Evidence map›Paper›PMID 28604798›Full record

ArticlePloS one2017

A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease.

Boris Hayete, Diane Wuest, Jason Laramie, Paul McDonagh, Bruce Church, Shirley Eberly, Anthony Lang, Kenneth Marek, Karl Runge, Ira Shoulson and 5 more

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.Movement disorders : official journal of the Movement Disorder Society · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Boris HayeteGNS Healthcare, Cambridge, Massachusetts, United States of America.
Diane WuestGNS Healthcare, Cambridge, Massachusetts, United States of America.
Jason LaramieNovartis, Cambridge, Massachusetts, United States of America.
Paul McDonaghAlexion Pharmaceuticals, Cambridge, Massachusetts, United States of America.
Bruce ChurchGNS Healthcare, Cambridge, Massachusetts, United States of America.
Shirley EberlyUniversity of Rochester, Rochester, New York, United States of America.
Anthony LangMorton and Gloria Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada.
Kenneth MarekInstitute for Neurodegenerative Disorders, New Haven, Connecticut, United States of America.
Karl RungeGNS Healthcare, Cambridge, Massachusetts, United States of America.
Ira ShoulsonGeorgetown University, Washington, DC, United States of America.
Andrew SingletonNational Institute on Aging, NIH, Bethesda, Maryland, United States of America.
Caroline TannerUniversity of San Francisco & San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America.
Iya KhalilGNS Healthcare, Cambridge, Massachusetts, United States of America.
Ajay VermaBiogen Idec, Cambridge, Massachusetts, United States of America.
Bernard RavinaVoyager Therapeutics, Cambridge, Massachusetts, United States of America.

Funding

Genome wide SNP analysis in Parkinson's diseaseZIAAG000949 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2024
$12.6M
Parkinson's Disease Data Organizing CenterU01NS050095 · NINDS · UNIVERSITY OF ROCHESTER · PI KURLAN, ROGER M · 2004 to 2010
$7.3M
NINDS NIH HHS U01 NS050095
6 · The paper itself

Abstract

backgroundThere are few established predictors of the clinical course of PD. Prognostic markers would be useful for clinical care and research.

objectiveTo identify predictors of long-term motor and cognitive outcomes and rate of progression in PD.

methodsNewly diagnosed PD participants were followed for 7 years in a prospective study, conducted at 55 centers in the United States and Canada. Analyses were conducted in 244 participants with complete demographic, clinical, genetic, and dopamine transporter imaging data. Machine learning dynamic Bayesian graphical models were used to identify and simulate predictors and outcomes. The outcomes rate of cognition changes are assessed by the Montreal Cognitive Assessment scores, and rate of motor changes are assessed by UPDRS part-III.

resultsThe most robust and consistent longitudinal predictors of cognitive function included older age, baseline Unified Parkinson's Disease Rating Scale (UPDRS) parts I and II, Schwab and England activities of daily living scale, striatal dopamine transporter binding, and SNP rs11724635 in the gene BST1. The most consistent predictor of UPDRS part III was baseline level of activities of daily living (part II). Key findings were replicated using long-term data from an independent cohort study.

conclusionsBaseline function near the time of Parkinson's disease diagnosis, as measured by activities of daily living, is a consistent predictor of long-term motor and cognitive outcomes. Additional predictors identified may further characterize the expected course of Parkinson's disease and suggest mechanisms underlying disease progression. The prognostic model developed in this study can be used to simulate the effects of the prognostic variables on motor and cognitive outcomes, and can be replicated and refined with data from independent longitudinal studies.

Indexed as

Bayes TheoremCognitionModels, TheoreticalMotor ActivityAgedAllelesComputer SimulationDisease ProgressionFemaleFollow-Up StudiesHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedModels, StatisticalParkinson Disease

Identifiers

PMID28604798
PMCPMC5467836

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.